Astressin analogues (corticotropin-releasing factor antagonists) with extended duration of action in the rat

Journal of Medicinal Chemistry

Volumn 41, Issue 25, 1998, Pages 5012-5019

  Rivier, Jean ^a   Gulyas, Jozsef ^a   Corrigan, Anne ^a   Martinez, Vicente ^b,c   Grey Craig, A ^a   Taché, Yvette ^b   Vale, Wylie ^a   Rivier, Catherine ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^c Departamento de Derecho Penal Edificio Seminario   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ASTRESSIN DERIVATIVE; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR DERIVATIVE; CORTICOTROPIN RELEASING FACTOR[12-41][12 DEXTRO PHENYLALANINE 21,38 NORLEUCINE]; UNCLASSIFIED DRUG;

ADRENALECTOMY; AMINO ACID COMPOSITION; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORTICOTROPIN RELEASE; DOSE TIME EFFECT RELATION; DRUG CONFORMATION; DRUG POTENCY; DRUG STRUCTURE; INTRACISTERNAL DRUG ADMINISTRATION; MALE; NONHUMAN; RAT; STOMACH EMPTYING;

ADRENALECTOMY; ADRENOCORTICOTROPIC HORMONE; AMINO ACID SEQUENCE; ANIMALS; CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CIRCULAR DICHROISM; CORTICOTROPIN-RELEASING HORMONE; ELECTROPHORESIS, CAPILLARY; GASTRIC EMPTYING; MASS SPECTROMETRY; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PEPTIDES, CYCLIC; PITUITARY GLAND, ANTERIOR; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032480913     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980426c     Document Type: Article

References (36)

1. Koerber, S. C.; Gulyas, J.; Lahrichi, S. L.; Corrigan, A.; Craig, A. G.; Rivier, C.; Vale, W.; Rivier, J. Constrained corticotropin-releasing factor (CRF) agonists and antagonists with i-(i+3) Glu-Xaa-DXbb-Lys bridges. J. Med. Chem. 1998, 47, 5002-5011.
2. Guillemin, R.; Rosenberg, B. Humoral hypothalamic control of anterior pituitary: a study with combined tissue cultures. Endocrinology 1955, 57, 599-607.
3. Saffran, M.; Schally, A. V. The release of corticotrophin by anterior pituitary tissue in vitro. Can. J. Biochem. Physiol. 1955, 33, 408-415.
4. Vale, W.; Spiess, J.; Rivier, C.; Rivier, J. Characterization of a 41 residue ovine hypothalamic peptide that stimulates the secretion of corticotropin and β-endorphin. Science 1981, 213, 1394-1397.
5. Rivier, J.; Spiess, J.; Vale, W. Characterization of rat hypothalamic corticotropin-releasing factor. Proc. Natl. Acad. Sci. U.S.A. 1983, 80, 4851-4855.
6. Shibahara, S.; Morimoto, Y.; Furutani, Y.; Notake, M.; Takahashi, H.; Shimizu, S.; Horikawa, S.; Numa, S. Isolation and sequence analysis of the human corticotropin-releasing factor precursor gene. EMBO J. 1983, 2 (5), 775-779.
7. Gulyas, J.; Rivier, C.; Perrin, M.; Koerber, S. C.; Sutton, S.; Corrigan, A.; Lahrichi, S. L.; Craig, A. G.; Vale, W.; Rivier, J. Potent, structurally constrained agonists and competitive antagonists of corticotropin releasing factor (CRF). Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 10575-10579.
8. Miranda, A.; Lahrichi, S. L.; Gulyas, J.; Koerber, S. C.; Craig, A. G.; Corrigan, A.; Rivier, C.; Vale, W.; Rivier, J. Constrained corticotropin releasing factor (CRF) antagonists with i-(i+3) Glu-Lys bridges. J. Med. Chem. 1997, 40, 3651-3658.
9. Perrin, M. H.; Sutton, S. W.; Rivier, J. E.; Vale, W. W. Comparison of an agonist, urocortin, and an antagonist, astressin, as radioligands for characterization of CRF receptors. JPET 1998, in press.
10. Martínez, V.; Rivier, J.; Wang, L.; Taché, Y. Central injection of a new corticotropin-releasing factor (CRF) antagonist, astressin, blocks CRF- and stress-related alterations of gastric and colonie motor function. J. Pharmacol. Exp. Ther. 1997, 280, 754-760.
11. Chrousos, G. P.; Gold, P. W. Editorial: A healthy body in a healthy mind - and vice versa - the damaging power of "uncontrollable" stress. J. Clin. Endocrinol. Metab. 1998, 83, 1842-1845.
12. Baram, T. Z.; Mitchell, W. G.; Haden, E. Inhibition of pituitaryadrenal secretion by a corticotropin releasing hormone antagonist in humans. Mol. Psychiat. 1996, 1, 320-324.
13. Chou, P. Y.; Fasman, G. D. Empirical predictions of protein conformation. Annu. Rev. Biochem. 1978, 47, 251-276.
14. Pallai, P. V.; Mabilia, M.; Goodman, M.; Vale, W.; Rivier, J. Structural homology of corticotropin-releasing factor, sauvagine, and urotensin I: Circular dichroism and prediction studies. Proc. Natl. Acad. Sci. U.S.A. 1983, 80, 6770-6774.
15. 1H NMR and distance geometry with restrained molecular dynamics Protein Eng. 1993, 6, 149-156.
16. Dathe, M.; Fabian, H.; Gast, K.; Zirwer, D.; Winter, R.; Beyermann, M.; Schumann, M.; Dienert, M. Conformational differences of ovine and human corticotropin releasing hormone. Int. J. Pept. Protein Res. 1996, 47, 383-393.
17. Rivier, J.; Rivier, C.; Vale, W. Synthetic competitive antagonists of corticotropin releasing factor: Effect on ACTH secretion in the rat. Science 1984, 224, 889-891.
18. Rivier, J.; Rivier, C.; Galyean, R.; Miranda, A.; Miller, C.; Craig, A. G.; Yamamoto, G.; Brown, M.; Vale, W. Single point D-substituted corticotropin releasing factor analogues: Effects on potency and physicochemical characteristics. J. Med. Chem. 1993, 36, 2851-2859.
19. Hernandez, J.-F.; Kornreich, W.; Rivier, C.; Miranda, A.; Yamamoto, G.; Andrews, J.; Taché, Y.; Vale, W.; Rivier, J. Synthesis and relative potencies of new constrained CRF antagonists. J. Med. Chem. 1993, 36, 2860-2867.
20. Miranda, A.; Koerber, S. C.; Gulyas, J.; Lahrichi, S.; Craig, A. G.; Corrigan, A.; Hagler, A.; Rivier, C.; Vale, W.; Rivier, J. Conformationally restricted competitive antagonists of human/ rat corticotropin-releasing factor. J. Med. Chem. 1994, 57, 1450-1459.
21. Felix, A. M.; Heimer, E. P.; Wang, C. T.; Lambros, T. J.; Fournier, A.; Mowles, T. F.; Maines, S.; Campbell, R. M.; Wegrzynski, B. B.; Toome, V.; Fry, D.; Madison, V. S. Synthesis, biological activity and conform at ional analysis of cyclic GRF analogues. Int. J. Pept. Protein Res. 1988, 32, 441-454.
22. Rivier, J.; Lahrichi, S. L.; Gulyas, J.; Erchegyi, J.; Koerber, S. C.; Craig, A. G.; Corrigan, A.; Rivier, C.; Vale, W. Minimal-size, constrained corticotropin releasing factor agonists with i-(i+3) Glu-Lys and Lys-Glu bridges. J. Med. Chem. 1998, 41, 2614-2620.
23. Hudson, D. J. Methodological implications of simultaneous solid-phase peptide synthesis. 1. Comparison of different coupling procedures. J. Org. Chem. 1988, 53, 617-624.
24. Kaiser, E.; Colescott, R. L.; Bossinger, C. D.; Cook, P. I. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal. Biochem. 1970, 34, 595-598.
25. Hoeger, C.; Galyean, R.; Boublik, J.; McClintock, R.; Rivier, J. Preparative reversed phase high performance liquid chromatography. II. Effects of buffer pH on the purification of synthetic peptides. Biochromatography 1987, 2, 134-142.
26. Rivier, J. Use of trialkylammonium phosphate (TAAP) buffers in reverse phase HPLC for high resolution and high recovery of peptides and proteins. J. Liq. Chromatogr. 1978, 7, 343-367.
27. Vale, W.; Vaughan, J.; Yamamoto, G.; Bruhn, T.; Douglas, C.; Dalton, D.; Rivier, C.; Rivier, J. Assay of corticotropin releasing factor. In Methods in Enzymology: Neuroendocrine Peptides; Conn, P. M., Ed.; Academic Press: New York, 1983; Vol. 103, pp 565-577.
28. Shoemaker, K. R.; Kim, P. S.; York, E. J.; Stewart, J. M.; Baldwin, R. L. Tests of the helix dipole model for stabilization of α-helices. Nature 1987, 326, 563-567.
29. Beyermann, M.; Fechner, K.; Furkert, J.; Krause, E.; Bienert, M. A single-point slight alteration set as a tool for structure-activity relationship studies of ovine corticotropin releasing factor. J. Med. Chem. 1996, 39, 3324-3330.
30. Rivier, J.; Rivier, C.; Perrin, M.; Porter, J.; Vale, W. GnRH Analogues Structure-activity relationships. In LHRH Peptides as Female and Male Contraceptives; Zatuchni, G. I., Shelton, J. D., Sciarra, J. J., Eds.; Harper and Row: Philadelphia, PA, 1981; pp 13-23.
31. ω-triazolyl-ornithine, -lysine or -para-aminophenylalanine residues at positions 5 and 6. J. Med. Chem. 1992, 55, 4270-4278.
32. Haskell-Luevano, C.; Boteju, L. W.; Miwa, H.; Dickinson, C.; Gantz, I.; Yamada, T.; Hadley, M. E.; Hruby, V. J. Topographical modification of melanotropin peptide analogues with betamethyl tryptophan isomers at position 9 leads to differential potencies and prolonged biological activities. J. Med. Chem. 1995, 38, 4720-4729.
33. Kertscher, U.; Beyermann, M.; Krause, E.; Furkert, J.; Berger, H.; Bienert, M.; Mehlis, B. The degradation of corticotropinreleasing factor by enzymes of the rat brain studied by liquid chromatography -mass spectrometry. Peptides 1998, 79, 649-658.
34. Felix, A. M.; Wang, C.-T.; Heimer, E. P.; Fournier, A. Applications of BOP reagent in solid-phase synthesis. II. Solid-phase side-chain to side-chain cyclizations using BOP reagent. Int. J. Pept. Protein Res. 1988, 31, 231-238.
35. Miller, C.; Rivier, J. Analysis of synthetic peptides by capillary zone electrophoresis in organic/aqueous buffers. J. Pept. Res. 1998, 57, 444-451.
36. Rivier, C.; Shen, G. H. In the rat, endogenous nitric oxide modulates the response of the hypothalamic-pituitary-adrenal axis to interleukin-1β, vasopressin and oxytocin. J. Neurosci. 1994, 14, 1985-1993.